2023
488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study
Khemani K, Stenger E, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Krishnamurti L. 488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Transplantation And Cellular Therapy 2023, 29: s366. DOI: 10.1016/s2666-6367(23)00556-0.Peer-Reviewed Original ResearchSecondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Eapen M, Brazauskas R, Williams D, Walters M, St Martin A, Jacobs B, Antin J, Bona K, Chaudhury S, Coleman-Cowger V, DiFronzo N, Esrick E, Field J, Fitzhugh C, Kanter J, Kapoor N, Kohn D, Krishnamurti L, London W, Pulsipher M, Talib S, Thompson A, Waller E, Wun T, Horowitz M. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Journal Of Clinical Oncology 2023, 41: 2227-2237. PMID: 36623245, PMCID: PMC10448940, DOI: 10.1200/jco.22.01203.Peer-Reviewed Original ResearchConceptsLow-intensity regimensSickle cell diseaseSecondary neoplasmsRisk factorsCell diseaseLeukemia/myelodysplastic syndromeMixed donor chimerismReduced-intensity regimensFull donor chimerismHematopoietic cell transplantTotal body irradiationLow-dose radiationGray regression modelsMyeloid mutationsPrior inflammationCell transplantMyelodysplastic syndromeTolerance inductionIntense regimensPlausible etiologyHigh riskRegimensSolid tumorsNeoplasmsMyeloid malignancies
2022
Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
George S, Veludhandi A, Xiang Y, Stenger E, Arnold S, Mehta A, Schirmer D, Spencer J, Guilcher G, Bhatia M, Abraham A, Gomez-Lobo V, Krishnamurti L, Meacham L. Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study. Blood 2022, 140: 1391-1392. DOI: 10.1182/blood-2022-168060.Peer-Reviewed Original ResearchFeasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study
Khemani K, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Stenger E, Krishnamurti L. Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Blood 2022, 140: 13043-13044. DOI: 10.1182/blood-2022-170685.Peer-Reviewed Original ResearchMultimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease
Bakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C, Sanders K, Peddineni M, Gillespie S, Keesari R, Krishnamurti L. Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease. Pediatric Blood & Cancer 2022, 70: e30046-e30046. PMID: 36322607, PMCID: PMC9820671, DOI: 10.1002/pbc.30046.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantPatient-reported outcomesSickle cell diseaseYear post-HCTPost-HCTExperimental pain sensitivitySickle cell anemiaCell transplantPain thresholdPain sensitivityCell diseaseCorrelates of painPressure pain thresholdHealth-related qualityCold pain thresholdAssessment of painPsychological factorsUnderstanding of painEffect sizePain assessmentObservational studySevere genotypePainCell anemiaOptional substudies58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
Stenger E, Chellapandian D, Shah R, Gillepsie S, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. 58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study. Transplantation And Cellular Therapy 2022, 28: s49-s51. DOI: 10.1016/s2666-6367(22)00219-6.Peer-Reviewed Original Research
2021
Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
Katoch D, Krishnamurti L. Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies. Patient Preference And Adherence 2021, 15: 2221-2229. PMID: 34629865, PMCID: PMC8493010, DOI: 10.2147/ppa.s264918.Peer-Reviewed Original ResearchSickle cell diseasePatient preferencesTreatment preferencesCell diseasePediatric sickle cell diseaseHematopoietic cell transplantPatients' treatment preferencesBurden of careQuality of lifeQualitative studyStandard gamble studyCurative intentRed blood cellsSupportive careSubstantial morbidityCell transplantImpaired qualityTreatment optionsIntravascular hemolysisPatient utilitiesPremature mortalityCaregiver perspectivesTreatment alternativesBlood cellsUtility studies
2018
Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell Transplant
Khemani K, Steele M, Bakshi N, Krishnamurti L, Yildirim I. Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell Transplant. Blood 2018, 132: 3406. DOI: 10.1182/blood-2018-99-119283.Peer-Reviewed Original ResearchHematopoietic stem cell transplantLate effects clinicStem cell transplantSickle cell diseaseLeukemia/lymphomaIDSA guidelinesPost-HSCTHigher oddsSCD patientsPPV-23Meningococcal vaccineElectronic medical recordsVaccine adherenceCell transplantVaccination ratesImmune deficiencyHematologic diseasesType of HSCTPost-hematopoietic stem cell transplantNon-malignant hematologic diseasesLast clinic visitRetrospective chart reviewInfectious Diseases SocietyPrimary care physiciansPediatric transplant programs
2017
Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives
Khemani K, Ross D, Sinha C, Haight A, Bakshi N, Krishnamurti L. Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives. Transplantation And Cellular Therapy 2017, 24: 1041-1048. PMID: 29196076, DOI: 10.1016/j.bbmt.2017.11.018.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantSickle cell diseaseStem cell transplantPatient-caregiver dyadsCell transplantCell diseaseSuccessful hematopoietic stem cell transplantAdult long-term survivorsTransplant-related morbidityDisease-related complicationsLong-term survivorsQuality of lifeSemistructured interview guideFocus group sessionsCurative intentHSCT decisionChildhood morbidityCaregivers' knowledgeHSCT experiencePremature mortalityDaily livingDecisional regretPatientsCaregiver perspectivesChild healthcare
2012
Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report
Dovey S, Krishnamurti L, Sanfilippo J, Gunawardena S, Mclendon P, Campbell M, Alway S, Efymow B, Gracia C. Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report. Journal Of Assisted Reproduction And Genetics 2012, 29: 265-269. PMID: 22219083, PMCID: PMC3288130, DOI: 10.1007/s10815-011-9698-2.Peer-Reviewed Original ResearchConceptsSickle cell diseaseSevere sickle cell diseaseHematopoietic stem cell transplantationStem cell transplantationVaso-occlusive eventsCell diseaseOvarian stimulationOvarian hyperstimulationFertility preservationCell transplantationOocyte cryopreservationHematopoietic stem cell transplantFertility preservation counselingGnRH antagonist protocolUnique patient populationStem cell transplantYear old femaleSuccessful ovarian stimulationAntagonist protocolCell transplantPatient populationOocyte bankingMulti-disciplinary teamElevated riskOld female